MA33666B1 - Procédé de traitement de troubles prolifératifs et d'autres états pathologiques à médiation par une activité kinase de bcr-abl, c-kit, ddr1, ddr2 ou pdgf-r - Google Patents

Procédé de traitement de troubles prolifératifs et d'autres états pathologiques à médiation par une activité kinase de bcr-abl, c-kit, ddr1, ddr2 ou pdgf-r

Info

Publication number
MA33666B1
MA33666B1 MA34769A MA34769A MA33666B1 MA 33666 B1 MA33666 B1 MA 33666B1 MA 34769 A MA34769 A MA 34769A MA 34769 A MA34769 A MA 34769A MA 33666 B1 MA33666 B1 MA 33666B1
Authority
MA
Morocco
Prior art keywords
ddr1
ddr2
abl
pdgf
treatment
Prior art date
Application number
MA34769A
Other languages
Arabic (ar)
English (en)
Inventor
Tomasz Szczudlo
Richard Woodman
Ophelia Yin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43222136&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33666(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA33666B1 publication Critical patent/MA33666B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un régime pour l'administration d'un pyrimidylaminobenzamide de formule I tel que défini présentement pour le traitement de troubles prolifératifs, en particulier de tumeurs solides et liquides, et d'autres états pathologiques à médiation par l'oncoprotéine Bcr-Abl, le récepteur tyrosine kinase transmembranaire cellulaire c-Kit, DDR1 (récepteur du domaine discoïdine 1), DDR2 (récepteur du domaine discoïdine 2) ou l'activité kinase de PDGF-R (récepteur du facteur de croissance dérivé des plaquettes).
MA34769A 2009-10-23 2012-04-10 Procédé de traitement de troubles prolifératifs et d'autres états pathologiques à médiation par une activité kinase de bcr-abl, c-kit, ddr1, ddr2 ou pdgf-r MA33666B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25432309P 2009-10-23 2009-10-23
PCT/US2010/053459 WO2011050120A1 (fr) 2009-10-23 2010-10-21 Procédé de traitement de troubles prolifératifs et d'autres états pathologiques à médiation par une activité kinase de bcr-abl, c-kit, ddr1, ddr2 ou pdgf-r

Publications (1)

Publication Number Publication Date
MA33666B1 true MA33666B1 (fr) 2012-10-01

Family

ID=43222136

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34769A MA33666B1 (fr) 2009-10-23 2012-04-10 Procédé de traitement de troubles prolifératifs et d'autres états pathologiques à médiation par une activité kinase de bcr-abl, c-kit, ddr1, ddr2 ou pdgf-r

Country Status (19)

Country Link
US (4) US20120202836A1 (fr)
EP (1) EP2490690A1 (fr)
JP (1) JP5948246B2 (fr)
KR (2) KR101853596B1 (fr)
CN (1) CN102647986A (fr)
AU (3) AU2010310705A1 (fr)
BR (1) BR112012009094A8 (fr)
CA (1) CA2777019A1 (fr)
CL (1) CL2012001012A1 (fr)
IL (1) IL219109A (fr)
MA (1) MA33666B1 (fr)
MX (1) MX2012004709A (fr)
NZ (1) NZ599217A (fr)
PH (1) PH12012500797A1 (fr)
RU (1) RU2012120901A (fr)
TN (1) TN2012000150A1 (fr)
TW (1) TWI592157B (fr)
WO (1) WO2011050120A1 (fr)
ZA (1) ZA201202413B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013068836A1 (fr) 2011-11-07 2013-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagoniste de ddr1 ou inhibiteur de l'expression génique de ddr1 destiné à être utilisé dans la prévention ou le traitement de la glomérulonéphrite rapidement progressive
JP6177768B2 (ja) * 2012-04-24 2017-08-09 中外製薬株式会社 ベンズアミド誘導体
HK1203943A1 (en) 2012-04-24 2015-11-06 中外制药株式会社 Quinazolinedione derivative
CA3134922A1 (fr) 2012-05-02 2013-11-07 Georgetown University Traitement d'une alpha-synucleinopathie au moyen d'inhibiteurs de la tyrosine kinase
EP3473250B1 (fr) * 2012-12-27 2022-08-17 Quest Diagnostics Investments Incorporated Mutations de ddr2 en tant que caractéristiques pouvant être ciblées d'un mélanome ou d'un carcinome à cellules basales
CN103965195B (zh) * 2013-02-01 2016-09-28 中国科学院广州生物医药与健康研究院 用于盘状结构域受体小分子抑制剂的化合物及其应用
PL3016667T3 (pl) * 2013-07-05 2023-02-06 Stellar Biome Inc. Probiotyczne szczepy bakteryjne do zapobiegania i leczenia chorób w jamie ustnej
AU2014338070A1 (en) 2013-10-23 2016-05-05 Chugai Seiyaku Kabushiki Kaisha Quinazolinone and isoquinolinone derivative
TW201718474A (zh) * 2015-08-31 2017-06-01 東麗股份有限公司 尿素衍生物及其用途
KR102902341B1 (ko) 2018-11-20 2025-12-18 조지타운 유니버시티 신경 변성, 심근 변성 및 리소좀 축적 장애를 치료하기 위한 조성물 및 방법
WO2020207570A1 (fr) * 2019-04-09 2020-10-15 Rottapharm Biotech S.R.L. Phénazines servant d'inhibiteurs de récepteurs 2 à domaine discoïdine (ddr2)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04012845A (es) 2002-06-28 2005-02-24 Nippon Shinyaku Co Ltd Derivado de amida.
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
EP1959957B1 (fr) * 2005-12-06 2012-07-18 Novartis AG Dérivés de pyrimidylaminobenzamide pour le traitement d'une neurofibromatose
US7729791B2 (en) * 2006-09-11 2010-06-01 Apple Inc. Portable media playback device including user interface event passthrough to non-media-playback processing
EP1923053A1 (fr) 2006-09-27 2008-05-21 Novartis AG Composition pharmaceutique comprenant de la nilotinib ou son sel
JP2010536775A (ja) * 2007-08-16 2010-12-02 アイアールエム・リミテッド・ライアビリティ・カンパニー 癌を処置するための方法および組成物

Also Published As

Publication number Publication date
MX2012004709A (es) 2012-05-23
ZA201202413B (en) 2013-03-27
RU2012120901A (ru) 2013-12-10
IL219109A (en) 2017-12-31
US20150313900A1 (en) 2015-11-05
JP2013508393A (ja) 2013-03-07
TWI592157B (zh) 2017-07-21
US20120202836A1 (en) 2012-08-09
WO2011050120A1 (fr) 2011-04-28
KR20120099650A (ko) 2012-09-11
JP5948246B2 (ja) 2016-07-06
US20140350037A1 (en) 2014-11-27
IL219109A0 (en) 2012-06-28
KR20170007868A (ko) 2017-01-20
AU2016216636B2 (en) 2018-06-07
CL2012001012A1 (es) 2012-10-26
TW201127383A (en) 2011-08-16
PH12012500797A1 (en) 2012-11-26
CA2777019A1 (fr) 2011-04-28
BR112012009094A2 (pt) 2016-05-03
NZ599217A (en) 2014-05-30
US20170143716A1 (en) 2017-05-25
CN102647986A (zh) 2012-08-22
AU2014202963A1 (en) 2014-06-19
KR101853596B1 (ko) 2018-04-30
TN2012000150A1 (en) 2013-12-12
BR112012009094A8 (pt) 2017-10-10
AU2010310705A1 (en) 2012-04-19
AU2016216636A1 (en) 2016-09-01
EP2490690A1 (fr) 2012-08-29

Similar Documents

Publication Publication Date Title
MA33666B1 (fr) Procédé de traitement de troubles prolifératifs et d'autres états pathologiques à médiation par une activité kinase de bcr-abl, c-kit, ddr1, ddr2 ou pdgf-r
MA33738B1 (fr) Procédé de traitement de troubles prolifératifs et d'autres affections pathologiques médiés par bcr-abl, c-kit, ddr1, ddr2 ou l'activité kinase du pdgf-r
MA38391A1 (fr) Dérivés de pyridinyl et triazolone pyridinyl de fusion
MA38380A1 (fr) Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)
MA47447B1 (fr) 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer
MA33450B1 (fr) Dérivés d'oxazine et leur utilisation en tant qu'inhibiteurs de bace pour le traitement de troubles neurologiques
MA35826B1 (fr) Triazolopyridines substituées et leur utilisation à titre d'inhibiteurs de ttk
MA33566B1 (fr) Thiohydantoïnes (hétéroarylméthyl) substituées utilisées comme médicaments anticancéreux
TN2014000420A1 (fr) Derives d'indole et d'indazole qui activent la mpk
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
TN2015000168A1 (fr) Inhibiteurs de la tyrosine kinase de bruton
MA34234B1 (fr) Composes pyrazol-4-yl-heterocyclyle-carboxamide et leurs procedes d'utilisation
NZ629198A (en) Oxazolidin- 2 -one compounds and uses thereof as pi3ks inhibitors
UA112055C2 (uk) Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну
MA35356B1 (fr) Dérivés de 2-amino-4-(pyridine-2-yl)-5,6-dihydro-4h-1,3-oxazine, et leur utilisation comme inhibiteurs de bace1 et bace2
TN2009000324A1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoides
MA34903B1 (fr) Derives de type azaindazole ou diazaindazole utilises comme medicaments
MA40955A (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA35674B1 (fr) Derives de chromone, leur procede de preparation et leurs applications therapeutiques
MA38648A1 (fr) Composés carboxamide de carbazole et de tétrahydrocarbazole substitués convenant comme inhibiteurs de kinases
EA200900783A1 (ru) Соединения и композиции в качестве ингибиторов киназы
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA35281B1 (fr) Dosage et administration d'anticorps anti-erbb3 en combinaison avec le paclitaxel pour le traitement de cancers gynécologiques
MA32061B1 (fr) Triazolopyridazines en tant qu'inhibiteurs de par1, production de celles-ci, et utilisation en tant que médicaments